問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Rheumatology

Division of Dermatology

Division of General Internal Medicine

Taichung Veterans General Hospital (在職)

Division of Rheumatology

Division of General Internal Medicine

China Medical University Hospital-Taipei (在職)

Division of Rheumatology

更新時間：2024-06-04

藍忠亮Lan, Joung-Liang
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 10 個月

Recruiting Trial

38Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

藍忠亮

List

109Cases

2023-10-13 - 2029-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2007-05-08 - 2011-05-08

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2005-05-01 - 2007-01-01

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2021-03-01 - 2027-04-01

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2007-04-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2020-08-27 - 2023-12-18

Phase II

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Guselkumab in Subjects With Active Lupus Nephritis

  • Condition/Disease

    Active Lupus Nephritis

  • Test Drug

    Guselkumab

Participate Sites
4Sites

Recruiting4Sites

2012-12-01 - 2015-12-31

Phase III

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite DMARD Therapy

  • Condition/Disease

    Active Rheumatoid Arthritis

  • Test Drug

    CNTO136

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

2012-12-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2009-09-01 - 2010-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2014-05-01 - 2020-12-31

Phase III

A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO136 (sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO136ARA3003 (SIRROUND-T)

  • Condition/Disease

    Rheumatoid Arthritis

  • Test Drug

    CNTO136 (sirukumab)

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

藍忠亮
China Medical University Hospital

1 4 5 6 7 8 11
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB